Dr. Jiang earned his Ph.D. in Medicinal Chemistry from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, followed by postdoctoral training at Oregon Health & Science University (OHSU) in the U.S. and served as a Visiting Professor at the University of California, Davis (UC Davis). He has been recognized as a Shanghai Oriental Talent (Leading Talent) and is a recipient of the Shanghai Talent Development Fund.
He previously held positions as an Associate Professor at Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine and as a Senior Researcher at WuXi AppTec. Dr. Jiang has been involved in the entire drug development chain—from small-scale and pilot-scale studies to industrial production—for drugs such as Liraglutide and YCH33. He possesses extensive experience in the industrialization of innovative drugs for major chronic and rare diseases of bone and joint, and has been responsible for pilot-scale production technology guidance and new drug R&D.As a project leader, he has undertaken multiple grants from the National Natural Science Foundation of China and Shanghai Municipal research projects. He has authored or co-authored over 40 publications as first or corresponding author in journals including Nature Communications, Journal of Medicinal Chemistry, and Journal of Bone and Mineral Research, and has filed 15 patent applications.
Dr. Jiang earned his Ph.D. in Medicinal Chemistry from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, followed by postdoctoral training at Oregon Health & Science University (OHSU) in the U.S. and served as a Visiting Professor at the University of California, Davis (UC Davis). He has been recognized as a Shanghai Oriental Talent (Leading Talent) and is a recipient of the Shanghai Talent Development Fund.He previously held positions as an Associate Professor at Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine and as a Senior Researcher at WuXi AppTec. Dr. Jiang has been involved in the entire drug development chain—from small-scale and pilot-scale studies to industrial production—for drugs such as Liraglutide and YCH33. He possesses extensive experience in the industrialization of innovative drugs for major chronic and rare diseases of bone and joint, and has been responsible for pilot-scale production technology guidance and new drug R&D.As a project leader, he has undertaken multiple grants from the National Natural Science Foundation of China and Shanghai Municipal research projects. He has authored or co-authored over 40 publications as first or corresponding author in journals including Nature Communications, Journal of Medicinal Chemistry, and Journal of Bone and Mineral Research, and has filed 15 patent applications.
